Advancing safe, legal and responsible ibogaine access worldwide.
The Ibogaine Global Institute is built around a simple but ambitious goal:
to transform decades of dispersed clinical experience into shared knowledge,
rigorous standards, high-quality research and better outcomes for patients.
To create an independent global institution capable of bringing together physicians, researchers, universities, specialists in cardiology, psychiatry, pharmacology, bioethics, public health and data science around a common purpose: to better understand ibogaine and raise standards for its responsible medical use.
Generate prospective, publishable knowledge.
Turn clinical experience into verifiable standards.
Build shared infrastructure to learn from every case.
Raise the capabilities of clinical teams.
Connect clinical and scientific communities worldwide.
The ibogaine field already contains many of the elements needed to advance: clinical experience, established centers, physicians with practical knowledge and academic researchers capable of rigorous science. The next step is to connect these elements through a shared global platform.
Years of accumulated clinical experience can become a valuable source of structured knowledge when it is documented, harmonized and studied systematically.
Universities, hospitals, research centers and specialists can contribute to studies, registries, standards and systems for evaluating outcomes.
Strong scientific infrastructure can generate better evidence on safety, outcomes and best practices while allowing countries and institutions to learn from one another.
IGI can provide the shared infrastructure the field currently lacks: a place where clinical experience is documented, compared, reviewed and progressively transformed into better practices.
Map existing clinical experience across countries.
Develop consensus-based clinical and safety standards.
Develop prospective multicenter registries.
Harmonize measures and methods across centers and researchers.
Train clinical teams and create continuous-improvement systems.
Publish results and share knowledge with the international scientific community.
IGI is envisioned as a scientific, medical, educational and public-benefit platform. Its purpose is to build the infrastructure, knowledge and professional capacity needed for responsible advancement of the field.
Promote, develop, coordinate, support and fund scientific, clinical, medical, pharmacological, epidemiological and outcomes research related to ibogaine and other interventions relevant to human health.
Develop, evaluate, update and disseminate standards, guidelines, protocols, criteria and best practices for patient selection, medical and psychiatric assessment, monitoring, administration, emergency preparedness, follow-up and integration.
Promote systems for quality, identity, purity, traceability, handling, storage and chain of custody for products used in research and authorized clinical settings.
Create, operate, support or collaborate on prospective registries, databases, outcomes platforms, pharmacovigilance and longitudinal follow-up systems that enable the study of safety, feasibility and clinical outcomes.
Establish partnerships with universities, hospitals, research centers, professional associations, civil-society organizations, foundations and national and international entities to advance knowledge and scientific projects of shared interest.
Develop continuing medical education, clinical training, competency certification, simulation, conferences, seminars, publications, educational materials and scientific outreach activities.
Design and evaluate tools, methodologies, assessment instruments, documentation systems, risk-management models and technologies that improve the quality and safety of clinical care.
Promote informed consent, transparency, data protection, bioethics, patient safety, risk reduction and learning systems based on adverse events and clinical outcomes.
Publish and disseminate results, reviews, consensus statements, recommendations, scientific materials and knowledge generated by IGI and its collaborators.
Enter into agreements, receive donations, obtain funding, administer resources and undertake lawful activities necessary to fulfill scientific, educational and public-benefit purposes on a nonprofit basis.
Success would not be measured only by publications or individual projects. It would be measured by the ability to create a culture of continuous learning around ibogaine worldwide.
Enable centers and professionals to assess, document and communicate clinical variables in comparable ways.
Move from fragmented case histories and retrospective reports to structured, longitudinal datasets.
Allow accumulated experience and new data to be continuously translated into better procedures.
Create infrastructure that enables collaborative prospective studies across institutions and countries.
Raise the capabilities of physicians, nurses, mental-health professionals and others involved in care.
Build an international community that generates knowledge, standards and innovation for the entire field.
The opportunity is to create a global learning system that learns from every patient, improves with every data point and shares that knowledge with the world.